Hubei Biocause Pharmaceutical Asset Resilience Ratio
Hubei Biocause Pharmaceutical asset resilience ratio. Hubei Biocause Pharmaceutical (000627) has an Asset Resilience Ratio of 0.78% as of September 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Hubei Biocause Pharmaceutical (000627) liquidity interval to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Hubei Biocause Pharmaceutical (2002–2023)
Asset resilience ratio of Hubei Biocause Pharmaceutical from 2002 to 2023. This chart shows how Hubei Biocause Pharmaceutical's Asset Resilience Ratio has changed over time. Read Hubei Biocause Pharmaceutical (000627) total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Hubei Biocause Pharmaceutical's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Hubei Biocause Pharmaceutical total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥2.24 Billion | 0.78% |
| Total Liquid Assets | CN¥2.24 Billion | 0.78% |
Asset Resilience Insights
- Limited Liquidity: Hubei Biocause Pharmaceutical maintains only 0.78% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Hubei Biocause Pharmaceutical Industry Peers by Asset Resilience Ratio
Compare Hubei Biocause Pharmaceutical's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
HDFC Life Insurance Company Limited
NSE:HDFCLIFE |
Insurance - Life | 0.68% |
|
Max Financial Services Limited
NSE:MFSL |
Insurance - Life | 0.29% |
|
Challenger Ltd
AU:CGF |
Insurance - Life | 2.14% |
|
Clearview Wealth Ltd
AU:CVW |
Insurance - Life | 22.11% |
|
Nobleoak Life Ltd
AU:NOL |
Insurance - Life | 11.03% |
|
Manulife Financial Corp
TO:MFC |
Insurance - Life | 0.95% |
|
Great-West Lifeco Inc.
TO:GWO |
Insurance - Life | 3.37% |
|
Power Corporation Of Canada
TO:POW |
Insurance - Life | 1.65% |
Hubei Biocause Pharmaceutical Asset Resilience Ratio by Year (2002–2023)
Hubei Biocause Pharmaceutical asset resilience ratio by year from 2002 to 2023. The table below shows the annual Asset Resilience Ratio data for Hubei Biocause Pharmaceutical.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 0.60% | CN¥1.80 Billion ≈ $263.16 Million |
CN¥301.94 Billion ≈ $44.18 Billion |
-0.13pp |
| 2022-12-31 | 0.72% | CN¥2.08 Billion ≈ $304.74 Million |
CN¥288.60 Billion ≈ $42.23 Billion |
-0.38pp |
| 2021-12-31 | 1.10% | CN¥2.91 Billion ≈ $425.46 Million |
CN¥263.90 Billion ≈ $38.62 Billion |
-0.39pp |
| 2020-12-31 | 1.49% | CN¥3.56 Billion ≈ $521.43 Million |
CN¥239.40 Billion ≈ $35.03 Billion |
+0.41pp |
| 2019-12-31 | 1.08% | CN¥2.21 Billion ≈ $323.66 Million |
CN¥205.27 Billion ≈ $30.04 Billion |
-1.89pp |
| 2017-12-31 | 2.97% | CN¥4.16 Billion ≈ $609.44 Million |
CN¥140.42 Billion ≈ $20.55 Billion |
+2.15pp |
| 2008-12-31 | 0.81% | CN¥16.08 Million ≈ $2.35 Million |
CN¥1.98 Billion ≈ $289.67 Million |
+0.57pp |
| 2007-12-31 | 0.24% | CN¥3.22 Million ≈ $470.89K |
CN¥1.32 Billion ≈ $193.82 Million |
+0.13pp |
| 2006-12-31 | 0.11% | CN¥1.34 Million ≈ $196.08K |
CN¥1.17 Billion ≈ $170.82 Million |
-0.01pp |
| 2002-12-31 | 0.12% | CN¥1.36 Million ≈ $199.30K |
CN¥1.09 Billion ≈ $159.56 Million |
-- |
About Hubei Biocause Pharmaceutical
Hubei Biocause Pharmaceutical Co., Ltd. primarily provides life and motor insurance products in China. It also engages in the pharmaceutical, chemical, and new energy fuel businesses. In addition, the company is involved in the contract research and production of APIs, intermediates, and formulations, including tablets, granules, capsules, etc.; and provision of chemicals comprising dimethyl ethe… Read more